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ABSTRACT 
Pneumocystis Carinii Pneumonia (PCP) and Pulmonary Tuberculosis (PTB) are the most frequent Opportunistic Infection (OI) in People living with 
HIV/AIDS (PLWHA), especially whose CD4 counts<200 cells/µL. There is no pathognomonic sign and symptom of pneumocystis, radiographic 
imaging (chest radiograph) and blood examination. An intractable microorganism cannot be isolated or sustained in culture. The diagnosis of PCP is 
complicated, based on the presumptive diagnosis. PCP should be treated optimally as soon as possible in order not to be fatal. We report a 
complicated case of a female 26 y-old, diagnosed with HIV infection on Highly Active Anti Retro Viral Therapy (HAART), PTB on Anti Tuberculosis 
Drugs (ATD) concurrent with PCP. She also has a history of various Drug Hypersensitivity Reactions (DHR) include Rifampycin, Ciprofloxacin and 
Cotrimoxazole. DHR is unpredictable, and Clindamycin and Primaquin are the recommended alternative drugs for PCP, the strategic therapy is by 
Desensitization Protocols. 
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INTRODUCTION  
Acquired Immunodeficiency Syndrome (AIDS) is a syndrome caused 
by the Human Immunodeficiency Virus (HIV) infection. Cluster of 
Differentiation (CD)-4 lymphocytes, which plays an important role 
in the immune system is the main target of HIV infection [1-3].  
PCP is an OI caused by Pneumocystis jirovecii, well-known as a major 
clinical manifestation of PLWHA defining diseases [4-6]. After the 
HIV pandemic, PCP and PTB became 2 of the frequent etiologic 
agents of OI associated with AIDS. The concurrent PCP and PTB are 
still as major causes of morbidity and mortality in PLWHA [7-9]. HIV 
infection causes immune deficiency, also leads to disregulation of 
the immune system, which increases DHR risk [10]. DHR in HIV 
infected patients often occurs; the previous study found to occur 100 
times more frequently than non-HIV patients [11]. In the case with 
DHR, which is unpredictable, the therapeutic approach is Rapid 
Desensitization [12-14]. 
We report a complicated case,a female 26 y-old, who was confirmed 
AIDS on HAART, PTB on treatment, also with the history of DHR 
(rifampycin, ciprofloxacin, cotrimoxazole), and developed PCP.  
CASE PRESENTATION  
A female patient, 26 y-old, came to Emergency Unit at General 




Fig. 1: The patient 
Shortness of breath felt since 7 d before admission. Shortness of 
breath was not influenced by the positional changes and activity. At 
the last 3 d admissions the shortness of breath was getting worse, 
she got a sleep disturbance. Patient also with productive cough, 
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yellow mucus, without blood. She also complained chest pain when 
coughing. Fever since 7 d before admission, loss of appetite 3 d 
before admission. No history of asthma, no history of smoking. The 
patient was confirmed with HIV infection previously with CD4 
lymphocyte count 13 sel/µl and has been taking HAART routinely. 
The HAART regimens were Tenofovir (TDF), Lamivudin (3TC) and 
Efavirenz (EFV). She also confirmed with PTB, took ATD, but she 
was hypersensitive to ATD, so the ATD was stopped. The ATD 
provocation test was performed with the conclusion hypersensitive 
to Rifampicin. Therefore ATD was continued by Rifampycin 450 mg 
oral Rapid Desensitization protocols, but there was an anaphylactic 
reaction to Rifampicin and therefore, the ATD was continued 
without giving Rimfapycin. She also has a history of DHR to 
Cotrimoxazole and Ciprofloxacin. In her family, there is no history of 
drug hypersensitivity. The social status; she is a laboratory worker 
and she has some sexual partner.  
The patient showed seriously ill, dyspnoe/chest discomfort, compos 
mentis, blood pressure 100/60 mmHg, pulse rate 104 x/minute 
regularly, respiratory rate 26 x/menit, 37.5 °C axillar temperature. 
On the Eye, Ear, Nose and Troat there were no abnormalities found, 
no Lymph node enlargment, no oral candidiasis and no cardiac 
abnormality. On the chest auscultation, we found bronchovesicular 
breath sounds; additional sound was rales at the left and right lungs, 
no wheezing. The Chest X-Ray impression: bilateral 
bronchopneumonia (fig. 2). 
 
 
Fig. 2: Chest radiograph (Chest X-Ray) 
 
The laboratory results: CBC; WBC 14,2 x 103/µl, neutrophil 11,0 x 
103/µl (77.3%), lymphocyte 2,1 x 103/µl (14.1%), monocyte 1 x 
103/µl (7.1%), eosinophyl 0.1 x 103/µl (0.8%), basophyl 0,0 x 103/µl 
(0,2%), haemoglobine 11.9 g/dL, MCV 83.6 fL, MCH 28.2 pg, HCT 
35.5%, PLT 351 K/µl. Blood Chemistry: liver and renal function 
within normal limits, On the Blood Gas Analysis; hypoxemia (pH: 
7,42; pCO2: 39 mmHg; pO2 80 mmHg; HCO3: 25,3 mmol/l; BE 0,8 
mmol/l; SO2 99%), Na 132 mmol/l; K: 3.2 mmol/l.  
Finally, the diagnosis was HIV infected patient (WHO stage IV) on 
HAART. She was also diagnosed with PTB concurrent with PCP. This 
patient had a history of DHR. Initial treatment was giving high 
calorie and high protein diet, isotonic infusion fluid, oxygen, 500 mg 
paracetamol tablet 3 time a day, bromhexin syrup 3xC1, 40 mg 
prednisone tablet 2 time a day, HAART (TDF/3TC/EFV).  
For PCP with Cotrimoxazole hypersensitive (Anaphylactic reaction) 
treated by giving an alternative antibiotic orally: 600 mg 
Clindamycin 4 time a day, 15 mg primaquin once a day. for 21 d with 
following Desensitization Protocols. Clindamycin with total dose 
2,400 mg a day with the initial dose 1/48 of 2,400 mg (50 mg) and 
primaquine 15 mg a day with the initial dose 1/10 of 15 mg (1,5 
mg). The Drug Provocation Test was followed by observation for 6 h 
as awareness to the drug hypersensitivity risk. There was no drug 
hypersensitivity reaction on the first and the second-day 
clindamycin oral provocation test (table 1). 
  
Table 1: Clindamycin oral provocation test (First and second day) [12] 
 Step Time (min) Cumulative time (min) Drug concentration Dose (mg) Cumulative dose (mg) 
1 0 0 1/48 50 50 
2 30 30 2/48 100 150 
3 30 60 4/48 200 350 
4 30 90 8/48 400 750 
5 30 120 16/48 800 1,550 
6 30 150 17/48 850 2,400 
 
On the third day treatment (Clindamycin Rapid Desensitization 
Protocols), at the step-4, cumulative time: 90 minutes, drug 
concentration 8/48, dose: 400 mg (Threshold dose) and cumulative 
dose: 750 mg, the patient complained a skin rash, itching.  
 
Table 2: Clindamycin oral provocation test (Third day) [12] 
 Step Time (min) Cumulative time (min) Drug concentration Dose (mg) Cumulative dose (mg) 
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1 0 0 1/48 50 50 
2 30 30 2/48 100 150 
3 30 60 4/48 200 350 
4* 30 90 8/48 400  750 (DHR+) 































*DHR= Drug Hypersensitivity Reactions, Under threshold dose estimation was 300 mg 
 
The estimation of safe and optimal under-threshold dose was 300 mg 
Clindamycin orally each 30 min until the usual daily dose was reached. 
In general inspection, she appeared fatigue, compos mentis, blood 
pressure 110/70 mm Hg, pulse rate 96 x/min regularly, respiratory 
rate 22 x/min. The conclusion; DHR to clindamycin and she was 
treated by diphenhydramine 10 mg injection intramuscular, 
methylprednisolone 125 mg injection intravenous. In a few minutes 
after treatment, the patient's condition was getting better.  
The therapy was continued by modifaid dose (the estimation of the 
safe and optimal under-threshold dose was 300 mg Clindamycin), 
each 30 min of drug concentration 6/48 until the usual daily dose 
(2,400 mg clindamycin) was reached (table 3). 
  
Table 3: Clindamycin treatment orally with rapid desensitization protocols (by modifaid dose under-threshold): 300 mg (Fourth day until 
21 d) [12] 
Step Time (min) Cumulative time (min) Drug concentration Dose (mg) Cumulative dose (mg) 
1 0 0 6/48 300 300 
2 30 30 6/48 300 600 
3 30 60 6/48 300 900 
4 30 90 6/48 300 1,200 
5 30 120 6/48 300 1,500 
6 30 150 6/48 300 1,800 
7 30 180 6/48 300 2,100 
8 30 210 6/48 300 2,400 
 
There was no DHR to Clindamycin by giving a modified dose (the 
estimation of safe and optimal under-threshold dose: 300 mg) each 
30 min until the usual daily dose was reached. 
On the fourth day treatment, the Clindamycin using dose 300 mg 
(6/48) every 30 min until the usual daily dose was reached. It was 
continued for 21 d with some suggestions to be aware of DHR risk. 
Primaquine Oral Provocation Test for 21 d (table 4). 
There was no DHR on the Primaquin Provocation Tests, therefore no 
primaquine modified dose. 
After 2 w follow up, the patient was getting better. The final regimen 
was Clindamycin 300 mg every 30 min until the usual daily dose was 
reached (Rapid Desensitization Protocols) and Primaquin 15 mg 
once daily was continued as an outpatient until 21 d, with some 
suggestions to be aware of DHR risk. 
 
Table 4: Primaquin oral provocation test [12] 
Step Time (min) Cumulative time (min) Drug concentration Dose (mg) Cumulative dose (mg) 
1 0 0 1/10 1.5 1.5 
2 30 30 2/10 3 4.5 
3 60 90 3/10 4.5 9 
4 90 180 4/10 6 15 
 
DISCUSSION  
The immune system can control in the early of the HIV infection, but 
occurred disruption of homeostasis and the function of other cells in 
the immune system in the advanced condition. Immune deficiency 
caused by the decreased number of CD4 lymphocytes causes 
opportunistic infections (OI). Pneumocystis Carinii Pneumonia 
(PCP) is one of the most frequent OI that might occur in 
immunocompromised patients, especially in people living with 
HIV/AIDS (PLWHA) with a CD4 lymphocyte counts less than 200 
cells/µL [15, 16].  
Th-1 and Th-2 CD4 lymphocytes are two subset of (CD)-4 
lymphocytes (T helper/Th), that are differentiated by the release of 
cytokines. Th-1 cells produce interferon-gamma (IFN-γ) and 
interleukin (IL)-2 these are the important mediators of cellular 
immune response. In the other hands Th-2 cells release IL-4, IL-5, IL-
6 and IL-10 (the humoral immune respon) that helps B cell 
lymphocytes release antibodies. HIV infection besides causes the 
immune deficiency, also leads to dysregulation of the immune 
system, the cytokines produced by Th-2 (IL-4) increases while the 
cytokines produced by Th-1 (IL-2) decreases. It supports the shift 
from predominance Th-1 to Th-2, which is caused by the increasing 
of hypersensitivity risk [13, 17, 18]. Other OI such Tuberculosis is 
also commonly found. Drugs Hypersensitivity Reactions (DHR) is 
hyperresponsiveness to the metabolites of drug based on 
immunological reactions [19, 20]. DHR is an adverse effect of drugs, 
and the mechanism may be mediated by T-lymphocytes or 
immunoglobulin [13, 21, 22].  
The risk of DHR in PLWHA is increasing. It as an important cause of 
morbidity in PLWHA who takes multi medication regimens. The 
diagnosis and therapy of DHR in PLWHA are essential to reach the 
optimal HIV infection outcome and to increase the quality of life. The 
discussion on this case focuses on the DHR [21, 23, 24].  
We report a complicated case, a female 26 y, people living with 
HIV/AIDS (PLWHA) on HAART, PTB on TB treatment (ATD), 
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suspected PCP, with experienced DHR to some antibiotics and ATD. 
A susceptibility to experience DHR began to occur after the 
appearance of symptom immunodeficiency. Previous study found 
that cotrimoxazole hypersensitivity reaction occured about 60% in 
PLWHA and 5% in immunocompetent. Introducing ATD such as 
isoniazid, pyrazinamide and rifampicin in PLWHA would be at risk 
of hypersensitivity reaction 20 times more often than those who non 
HIV infected. The drugs which were reported hypersensitivity 
reactions in PLWHA were cotrimoxazole, penicillin, antiretroviral, 
antituberculosis, anticonvulsants, and non-steroidal anti-
inflammatory drugs (NSAIDs) [11, 25, 26].  
The dysregulation of the immune system caused by the predominace 
Th1 to Th2 which is followed by the cytokine profile likely plays a role 
besides other factors, such as oxidative stress, hyperactivation of the 
immune system, changes in drug metabolism, genetic susceptibility are 
suspected to contribute to the mechanism [11, 27, 28].  
In this case, the patient has a hypersensitive reaction when 
consuming ATD, a skin rash and itching over all the body. The 
conclusion of ATD provocation test is anaphylactic reaction to 
Rifampycin, therefore the ATD is continued without giving 
Rifampycin. The case also with PCP and has history anaphylactic 
reaction to Cotrimoxazole. The management in the event of 
hypersensitivity reactions to drug in PLWHA is discontinued or to 
avoid drugs trigger hypersensitivity reactions and to replace other 
drugs with the same therapeutic purpose. Rapid desensitization is 
the recommended therapeutic approach, with the main purpose for 
the underlying disease in hypersensitivity reactions will disappear 
along with the recovery of the immune system [29-31]. 
CONCLUSION 
We reported a case, a female 26 y old, Balinese with HIV infected 
patient (WHO stage IV) on HAART, Pulmonary Tuberculosis on 
Treatment, Pneumocystis Carnii Pneumonia and drug hyper-
sensivity to Cotrimoxazole, Cyprofloxacine and Clindamycin. Rapid 
Desensitization is the therapeutic approach protocols, with the aim 
essentially for the underlying disease in which hypersensitivity 
reactions will disappear along with the improvement of the immune 
system. 
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